Note: Descriptions are shown in the official language in which they were submitted.
CA 02206803 1997-06-03
W O 96/19207 PCT/SE95/01541
r Powder formulations containing melezitose as a diluent
Field of the invention
The present invention relates to powder formulations cont~ining mPrlir~lly useful
s polypeptides.
Technic~l back~round
Polypeptide powders Cont~ining m~Aic~lly useful polypeptides and ph~rrn~reutic~lly
acceptable carriers or ~liluentc may be prepared for ~rlmini.~tration by inhalation or
o otherwise. Inhalable polypeptide powder preparations have been described in
WO95/00127 and W095/00128.
Diluents are cornmonplace in ph~ ceutit~l p~ tions, especi~lly in formulations for
inh~l~tion. They are used to stabilise various drugs during m~n-.r~ .t and storage and to
adjust the a-m--ount of powder m~kin~ up unit doses - in general, powder inh~lP~ are
capable of delivering a drug ~ubsL~ce with good dose accuracy only for certain dose sizes,
while dirre~c.1t drugs have different potencies and must therefore be delivered in dirre~ t
amounts. As these amounts are often too small for proper dose accuracy to be ensured,
diluents are added to give the desired dose size.
Previously, reducing sugars such as lactose and glucose have been used as ~ çn~ in
polypeptide powder formulations. These however have a tendency to react with
polypeptides and are therefore llnc~ti~factory.
~5 It is suggested in W095/00127 and W095/00128, relating to polypeptide powders for
inh~ tion, that non-reducing sugars such as raffinose, melezitose, lactitol, maltitol,
trehalose, sucrose, m~nnitol and starch may be preferred additives for the polypeptide
powders.
CA 02206803 1997-06-03
W O96119207 PCTISE95101541
It has now been found that melezitose is an exceptionally good diluent colllp~cd with
other possible non-reducing sugar diluents for polypeptide powder formulations, giving an
unexpectedly high respirable fraction of powder when inhaled.
Surnrnarv of the invention
Accordingly, the present invention provides a powder formulation for the a~lmini~tration
of m~rli~lly useful polypeptides, compricin~ a m~ lly useful polypeptide with
mç1ezitQse as diluent.
~-lmini~tratjon is preferably by inhalation.
The .-~k~ Qse may comprise for exarnple D~ .7;~0~ x-D-mPle7.itose), ~-~
gluco~y~ osi-l~, ~a-D- gluco~ldnosyl-l,3-~-D-fructofuranosyl (~-D-m~1e7.i~ose) or
15 i~ol~ .;lusc. The mel~z.itose may be for exarnple in the fonn of the mono~d~ or
dihydrate.
The powder forrnulation of the present invention has b~en found to be very effective upon
oral inhalation, giving a superior fraction of respirable particles compared u ith powder
20 formulations with other diluents, as is described herein. As a result, a higher fraction of
the inhaled powder will reach the lungs and a higher fraction of the polypeptide is nti1i~e~1
The powder formulation of the present invention is also suitable for use in nasal inhalation.
25 The powder formulation of the present invention is suitable for both systerruc and local
treatment. When local action is desired in the respiratory tract, no other ingredient is
necesS~ry in the powder formulation. When systemic action is required, an enh~ncer, i.e. a
substance which enhances the absorption of the polypeptide in the respiratory tract, should
generally be included in the formulation. Such substances are included in W095/00127
30 and W095/00l28, incorporated herein by reference. In certain cases, small polypeptides
are absorbed in the respiratory tract without the aid of an enhancer. In these cases an
CA 02206803 1997-06-03
W O 96/19207 PCT/SE9S/OlS41
enh~ncer may be excluded from the formulations of mele7itose and the medically useful
polypephde. In different embotlimPrlt~ therefore the present invention provides a powder
comprising a medically useful polypeptide and melezitose; a powder comprising a
m.o-liç~lly useful polypeptide and melezitose and specifically including an er h~n~er; and a
s powder comprising a medically useful polypeptide and melezitose, specifically excluding
an ~nh~nrer. The powder according to the present invention excluding an enh~ncer~ is most
useful (a) when local action of the polypeptide is desired; or (b) when systemic action of
smaller polypeptides which are absorbed in the re~.~hd~o,y tract without the aid of an
enhancer is desired. Polypeptides which are absorbed in the le;~ aloly tract without the aid
o of an enh~ncer may be identified using conventional cell or, preferably, animal models, in
the latter case by co-~lp~ g plasma polypeptide levels following ~Aministration7 for
example by means of a Wright Dust Feed a~aldLus, of powders with and without
çnh~n~r. The ~wd~r spe~ifi~ ~lly incl~ in~ an çnh~n~çr acc~ g to the present
invention, is most useful when systemic action of polypeptides which are not abso,l,cd in
the l~s~ tol~ tract without the aid of an Pnh~nrPr, is desired.
Preferred enh~n~ ers include C8 l6 fatty acids and salts thereof, bile salts, phospholipids and
aLkyl sacch~ri~les
Of the fatty acids and salts thereof, Cg-CI6 fatty acids salts are preferred. Examples of
preferred fatty acid salts are sodium, potassium and Iysine salts of caprylate (Cg), caprate
(C10), laurate (C~2) and myristate (Cl4). As the nature of the counterion is not of special
signifi~nce, any of the salts of the fatty acids are potentially useful. A particularly
~-~fel.cd fatty acid salt is sodium caprate.
~5
~ Suitable bile salts may be for example salts of cholic acid, chenodeoxycholic acid,
glycocholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic
acid, deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, lithocholic acid, and
ursodeoxycholic acid.
CA 02206803 1997-06-03
W 096/19207 PCT/SE9S/01541
Of the bile salts, trihydroxy bile salts are preferred. More preferred are the salts of cholic,
glycocholic and taurocholic acids, especially the sodium and potassium salts thereof. The
most preferred bile salt is sodium taurocholate.
s Suitable phospholipids may be for example single-chain phospholipids, for example
lysophosphatidylchc-linPc, lysophosph~ti~lylglycerols, lysophosphatidyleth~nt~l~min~c,
lysophosphatidylinositols and lysophosphatidylserines or double-chain phospholipids, for
example diacylphosphatidylcholines, diacylphosphatidylglycerols,
diacylphosphatidylethanol~minPs, diacylphosphatidylinositols and
o diacylphosphatidylserines.
Of the phospholipids, diacylphosphatidylglycerols and diacylphosphatidylcholines are
d, for example dioctan~lphosphaLidylglycerol and dioctanoylphosph~ti-lylcholine.
IS Suitable aLkyl s~qcc-h~ri(les may be for e~mple aLkyl glucosides or alkyl m~ltosi~les, such as
decyl glllcoci~le and dodecyl m~lt~ e,
The most preferred enhancers are bile salts.
The polypeptide may be any medically or diagnostically useful peptide or protein of small
to mPtlillm size, i.e. up to about 40 kD molecular weight (MW). It is expected that
polypeptides having a molecular weight of up to 30 kD will be most useful in the present
invention, such as polypeptides having a molecular weight of up to 25 kD or up to 20 kD,
and especially up to 15 kD, up to lOkD, or up to 5 kD.
The polypeptide is preferably a peptide hormone such as insulin, glucagon, C-peptide of
insulin, vasopressin, desmopressin, corticotropin (ACTH), corticotropin releasing
hormone (CRH), gonadotropin releasing horrnone (GnRH), gonadotropin releasing
hormone agonists and antagonists, gonadotrophin (luteinizing hormone, or LHRH),
calcitonin, parathyroid hormone (PTH)~ bioactive fragments of PTH such as PTH(34) and
PTH(38), growth hormone (GH) (for example human growth hormone (hGH)), growth
CA 02206803 1997-06-03
W O 96/19207 PCTISE95101541
s
hormone rele~cin~ horrnone (GHRH), somatostatin, oxytocin, atrial natriuretic factor
(ANF), Ihylot,o~ releasing hormone (TRH), deoxyribonuclease (DNase), prolactin, and
follicle stim~ ting hormone (FSH), and analogues of any of the above.
Other possible polypeptides include growth factors, interleukin~, polypeptide vaccines,
enzymes, endorphins, glycoproteins, liL)~pl-)teins, and polypeptides involved in the blood
coagulation c~cc~le.
The preferred polypeptide is insulin.
In the powder form~ tion of the present invention melezitose may be present in an amount
of up to almost 100% by weight of the total powder. For example the mele7.itQse may be
present in an arnount bet~. _cn 20% and almost 100%, for e~cample ~L.. ~n 30% and
almost 100% or be~ 40% and almost 100%, or '~l-.~n 50% and almost 100%, e.g
lS between 60% and almost 100%, or between 65% and alrnost 100%, such as l~l~. ~n 65%
and 99% or bet~ around 70% and around 99% such as bel~ 80% and 98% by
weight of the total weight of powder.
As with all pharmaceutical preparations, certain additives, for exarnple for pH regulation,
for example organic or inorganic salts, to give taste, or to increase stability, for example
preservatives, carbohydrates, amino acids, peptides and proteins, may also be included in
the formulation.
When the powder ~ pa.~lion of the present invention is inten-lçd for oral inhalation the
2s polypeptide should consist of (a) primary particles having a ~ m~-ter of less than about 10
microns, for exarnple between 0.01 and 10 rnicrons and preferably between 0.1 and 6
microns, for example between 0.01 and 5 micons, or (b) agglomerates of said particles.
Preferably at least 50% of the polypeptide consists of particles witnin the desired size
range. For example at least 60%, preferably at least 70%, more preferably at least 80% and
~ 30 most preferably at least 90% of the polypeptide consists of particles within the desired size
range, when oral inhalation is desired.
CA 02206803 1997-06-03
W 096/19207 PCT/SE9S/OlS41
The melezitose in the form~ tion for oral inhalation may largely consist of particles having a
mPtPr of less than about 10 microns so that the resultant powder as a whole consists of
optionally agglom~ratPA primary particles having a ~ mPter of less than about 10 microns;
s ~l~ern~tively the mPlç7itose may largely consist of much bigger particles ("coarse particles"),
so that an "ordered mL~ture" may be formed b~l~..~n the active compounds and them~l~7itose. In the ordered mixture, ~ltçr.-~tively known as an interactive or adhesive mixture,
the polypeptide particles will be fairly evenly distributed over the surf~ of the coarse
...clo~i~ose Preferably in such case the active compounds are not in the form of agglomerates
~o prior to formation of the ordered ~ lu~G. The coarse particles may have a ~ mPter of over
20 microns, such as over 60 microns. Above these lower limits, the ~ mPtçr of the coarse
particles is not of critical im~ol ~nce so various coarse particle sizes may be used, if desired
accol~ling to the practical ~G~Uil~ S of the particular fonnlll_tion There is no l~UilG~.lt
for the coarse particles in the ordered mixture to be of the same size, but the coarse particles
IS may advantageously be of similar size within the ordered ll~L~ Gfc.~ly, the coarse
particles have a ~ ,. .t~ .l of 60 - 800 c~s.
The particle size is less important in nasal inhalation although small par~icles are desirable.
An ordered mixture would not normally be employed in nasal inhalation.
A useful mP~h~-nicm for delivery of the powder into the respiratory tract of a patient is
through a portable inhaler device suitable for dry powder inhalation. Many such devices,
typically designed to deliver ~nti~cthm~tic or ~ntiinfl~mmi tory agents into the l~;tlJllal~lly
system, are on the market.
2s
The described powder preparation can be m~nl-f~rtured in several ways, using con~entional
techniques. Particles in a required size range may be obtained by any known method, for
example by freeze-drying or by controlled crystallisation methods, for example crystallisation
using supercritical fluids; or by rnicronisation methods. For example, one can dry rnix the
polypeptide and melezitose (and optional e~h~ncer) powders, and then micronise the
substances together; alternatively, the substances can be micronised separately, and then
CA 02206803 1997-06-03
W Og6/19Z07 PCT/S~9S/01541
mixed. Where the colllpounds to be rnixed have dirrel~,nt physical properties such as
- hardness and brittlen~ss, recict~n~e to microrlisation varies and they may require ~lirrel~ent
pressures to be broken down to suitable particle sizes. When microrused together, therefore,
the obtained particle size of one of the col~ or.ents may be llnc~ticf~rtory. In such case it
s would be advantageous to micronise the di~erent co~ ents separately and then rnix them.
It is also possible, where an ordered llli~lul~ is not int~nlleA, first to dissolve the components
in a suitable solvent, e.g. water, to obtain mixing on the molecular level. This procedure also
makes it possible to adjust the pH-value to a desired level. To obtain a powder, the solvent
o must be removed by a process which retains the polypeptide's biological activity. Suitadble
drying methods include vacuum concentration, open drying, spray drying, and freeze drying.
Telll~dLllres over 40~C for more than a few minutes should generally be avoided, as some
degradation of the polypeptide may occur. Following the dIying step, the solid m~t~.ri~l can,
if n~cs~ry~ be ground to obtain a coarse ~w~el~ then, if ~ cs~- ~, rnicronised
IS
If desired, the powder can be ~ C~ to imE~rove the flow ~JlU~.Lies, e.g., by drygranulation to form sph~rir~1 ~gglo.~ S with superior h~nrlling ~ CI~' ;CI irc, before it is
incorporated into thè int~n~le-l inhaler device. In such a case, the device would be configured
to ensure that the agglomerates are subst~nfi~lly deagglomerated prior to exiting the device,
SO that the particles çnt~ring the respiratory tract of the patient are largely within the desired
slze range.
Where an ordered mixture is desired, the active compound may be processed, for example by
micronisation, in order to obtain, if desired, particles within a particular size range. The
melezitose may also be processed, for exarnple to obtain a desired size and desirable surface
pro~eLLies, such as a particular surface to weight ratio, or a certain nlgg~rlnçs~, and to ensure
optimal adhesion forces in the ordered mixture. Such physical requirements of an ordered
mixture are well known, as are the various means of obtaining an ordered rnixture which
fulfills the said requirements, and may be determined easily by the skilled person accoldillg to
the particular circumct~nl~es.
CA 02206803 1997-06-03
W O 96/19207 PCTtSE9S/OlS41
The powders of the present invention are useful for the local or systemic tre~tm~nt of ~licç~cec
and may be ~mini.~tered for example via the upper and lower respiratory tract, including by
the nasal route. As such the present invention also provides said powder for use in therapy;
the use of the powder in the m~nnfartl-re of a medicarnent for the tre~tmP~t of dice~ces via
the respiratory tract; and a method for the treatm~nt of a patient in need of therapy,
comprising ~tlminictçrin~ to said patient a therapeutir~lly effective amount of the powder
of the present invention.
The tlice~ces which may be treated with the powder of the present invention are any of
lO those which may be treated with the particular polypeptide in each case; for example
powders cont~ining insulin according to the present invention may be used for example in
the treatment of diabetes; powders cont~ining corticotropin may be used for example in the
of infl~mm~tory ~l;c~es; powders cont~inin~ GnRH ~ay be useful for ~x~r~
in the [~ P.nt of male infertility. The in-lic~tiQns for all of the m~ntion~d polypeptides
15 are well known. The powders of the present invention may also be used in prophylactic
Although the powders of the present invention are particularly directed to polypeptide
powders for inhalation from dry powder inhaler devices, the polypeptide powders may also
20 be included in compositions for other forms of ~tlmini~tration, for example in injection
solutions and aerosol form~ tions.
The respirable fraction upon oral inhalation of the powders of the present invention may be
determinecl by the method described in the Examples herein.
Certain embo lim.~.r~tc of the invention are illustrated in the following Examples, which are
not to be considered limitin~:
Example 1
30 Insulin (O.~ig) was dissolved in distilled water (50 ml). Diluent ( 14.4g) was added and
dissolved and the pH was adjusted to 7.4. The obtained solid cake was crushed, sieved, and
CA 02206803 1997-06-03
W O 96/19207 PCTISE9S/OlS41
rnicronised in a jet rnill. The rnicronised powders were agglomerated and filled into a
Turbuhaler ~ dry powder inhaler and the dose was released at an air flow rate of 60 I~min,
under varying conditions.
s The released dose was collected using a multi-stage impinger; the content of insulin in each
stage of the impinger was det~minto-d using liquid chromatography with detection at 235
nm. The results were as follows.
fraction of 30%RH, 75%RH, 30%RH,
particles of size 60 L/min 60 Ilmin 60 L~rnin,
less than 6.8 llm, open moisture
% provocation**
Diluent
myo-ino~itol 52 18 3
m~ltitol 66 1O 8
m~nnitol 65 17 9
trehalose 58 22 17
raffinose 40 17
p~l~tinite 30 18 15
stachyose 52 5
mlole7itQse 73 3 32
o ** the preparation had been moisture provocated for three days in open plates.
It is clearly seen that melezitose gave the highest fraction of respirable particles in all cases.
Moreover the respirable fraction is not as dependent on external factors when melezitose is
the diluent.
CA 02206803 1997-06-03
W O 96119207 PCT/SE95/01541
Example 2
Insulin (12 parts) was dissolved in .li~till~l water. Sodium taurocholate (enhancer, 4 parts)
was added. Various diluents (84 parts) were added and dissolved and the pH was adjusted
to 7.4. The solution was concentrated by evaporation of the water. The obtained solid
s cake was crushed, sieved, and micronised in a jet mill.. The micronised powder was
agglomerated and filled into a Turbuhaler ~ dry powder inhaler and the dose was released at
an air flow rate of 60 I~rnin, under varying conditions.
The released dose was collected using a multi-stage impinger; the content of insulin in each
o stage of the impinger was (ieterrnin~d using liquid chromatography with detection at 235
nrn. The results were as follows.
Fraction of particles of 30% RH 90% RH
size less than 6.8 ~m, % 60 L/min 60 Ilmin
,llrl~7;l~se 65.0 21.7
trehalose 60.5 6.3
myo-inositol 71.6 10.9
mannitol 79.4 4.4
maltitol 44.7 0.1
These results show that the fnnnul~tion with melezitose is much less affected by high
hllmi~ity in the air.
Example 3
Micronised formulations containing DNase, surfactant (sodium taurocholate or
dioctanoylphosphatidylglcerol), and melezitose (ratio DNase: surfactant: melezitose 1:
0.33: 98.67, total weight 50 mg), were added to propellant 134a or propellant 227
(approximately 10 ml) in a plastic coated glass bottle. The formulations were mixed with
an ultra turrax for approximately 10 minutes.
CA 02206803 1997-06-03
W O 96/19207 PCT/SE95/01541
11
Identical formulations were prepared to which 5% of ethanol prior to the mixing with an
ultraturrax apparatus for approximately 10 minutes.
s The quality of the sl-cpencions forrned were ~csçcsed imm~ t~ly and after 20 hours. In all
cases good suspensions were observed.
This shows that the m~le~itose-cont~inin~ forrnulations of the present invention are
suitable for use in for-m--ulations other than for dry-powder inhalation, in this case in aerosol
o formulations.